Lumida
/QURE
⌘K
Uniqure NV

Uniqure NV

QURE
$40.25USD↑+2.26%+0.89 today

MARKET CAP

2.7B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$38 – $41

52W RANGE

$9
$72

AI Summary

Stalk
StalkMedium

QURE remains in a high‐conviction Stage 2 advance underpinned by a Momentum Breakout, with clear higher highs and higher lows and price riding well above rising EMAs. Both long‐ and medium‐term directional biases are bullish, but current extreme overbought readings and significant extension above the 9/21/50 EMAs argue against immediate entry. The optimal engagement is to Stalk, awaiting a pullback into the rising EMAs or prior consolidation zone for a higher‐probability buy.

  • ↑AMT-130 delivered a 75% slowdown in Huntington’s disease progression over three years.
  • ↑Breakthrough therapy designation and MHRA engagement accelerate approval path.
  • ↓Revenues fell from $16.1M in Q4 2025 to $3.6M in Q1 2026.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

uniQure N.V. (NASDAQ:QURE) is a biotechnology company that focuses on developing innovative gene therapies for severe genetic diseases, specifically targeting conditions like Huntington's disease, Fabry disease, and temporal lobe epilepsy. The company is positioned at the forefront of the gene therapy market, with its lead candidate AMT-130 being developed as a potential first disease-modifying treatment for Huntington's disease. With promising initial clinical results and significant backing for regulatory submissions, uniQure aims to address the pressing unmet medical needs within the rare disease space.

Bull says

  • ↑AMT-130 delivered a 75% slowdown in Huntington’s disease progression over three years.
  • ↑Breakthrough therapy designation and MHRA engagement accelerate approval path.
  • ↑Cash reserves of $586.6M fund clinical and commercial goals into late 2029.
  • ↑High institutional ownership and strong momentum factors underpin investor confidence.
  • ↑Upcoming AMT-260 epilepsy data could broaden pipeline value.
  • ↑Liquidity factor strong; positive dividend yield and momentum factors support the thesis.

Bear says

  • ↓Revenues fell from $16.1M in Q4 2025 to $3.6M in Q1 2026.
  • ↓Negative earnings yield and weak profitability raise capital attraction risk.
  • ↓FDA feedback may require a Phase III trial, delaying BLA submission.
  • ↓Reimbursement pathways remain uncertain, posing commercial risk.
  • ↓Market skepticism on AMT-130 projections could drive stock volatility.
  • ↓Uncertain growth outlook and small size hinder competitive positioning.

Investment themes with QURE

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 06-01-2026bullish

Transcript signals

Bull points

  • 2025 has the potential to be a transformational year for the company, with multiple important value-driving milestones ahead.
  • In April, the FDA granted breakthrough therapy designation, underscoring both the urgent need in Huntington's disease and the strength of our clinical data.
  • Last year, we significantly reduced our cash burn with the divestiture of our GMP manufacturing facility, and organizational restructuring.

Bear points

  • three serious adverse events related to immunosuppression. Mania, which is a well-known adverse event of prolonged corticosteroid therapy, and infection and fever, which probably are related to the triple regimen of immunosuppression. And all of these events fully resolved with standard care interventions.
  • Revenue for the first quarter was $1.6 million compared to $8.5 million in the same period of 2024. The decrease of $6.9 million in revenue was mainly from a decrease of $3.3 million of collaboration revenue and a decrease of $4 million in contract manufacturing revenue.
  • Cost of contract manufacturing revenues were nil in the first quarter compared to $9.1 million for the same period in 2024.
Read full transcript analysis ›